• PDF / 169,470 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 27 Downloads / 163 Views

DOWNLOAD

REPORT

---

1 S

Nausea and allergic reactions: 2 case reports In a retrospective study of 51 women with small cell carcinoma (SCC) of the cervix treated between 2010 and 2015, two women [exact ages not stated] were described, of whom, one woman developed nausea during treatment with irinotecan and nedaplatin, while the other woman developed allergic reaction to nedaplatin. The women, who were diagnosed with metastatic SCC of the cervix, underwent radical hysterectomy and systematic pelvic lymphadenectomy. Thereafter, the women started receiving nedaplatin [dosage and route not stated] on day 1 and IV irinotecan [CPT-11] 60 mg/m2 on day 1 and other day (either day 8 or 15 of chemotherapy; not specified) of each chemotherapy cycle. However, one woman developed allergic reactions to nedaplatin. Therefore, her nedaplatin therapy was switched to cisplatin from the second cycle onwards. The other woman developed grade 3 nausea, and the dose of nedaplatin was decreased at the second cycle of chemotherapy [not all time to reaction onsets stated; outcomes not stated]. Matsuoka H, et al. UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving 803502190 irinotecan chemotherapy: a retrospective study. BMC Cancer 20: 5 Aug 2020. Available from: URL: http://doi.org/10.1186/s12885-020-07225-1

0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 19 Sep 2020 No. 1822